Endocrine Society's 2021 Annual Meeting
Posters:
Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared With Daily Somatropin in Pediatric Patients With Growth Hormone Deficiency (GHD)
Results From an Open-Label Extension of the Phase 2 Dose-Finding Study of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency (GHD)
Phase 3 Study Evaluating Once Weekly Somatrogon Compared to Daily Genotropin in Japanese Patients With Pediatric Growth Hormone Deficiency (pGHD)
Abstracts:
Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared to Daily Somatropin in PediatricPatients With Growth Hormone Deficiency (pGHD)
Comparison of Quality of Life Responses From Caregiver and Children Aged ≥ 7 Years Using the Quality of Life in Short Stature Youth (QoLISSY)Questionnaire, Following 12 Months of Growth Hormone Treatment With Either a Weekly Somatrogon or a Daily Genotropin Injection Schedule
Results From an Open-label Extension of the Phase 2 Dose Finding Study of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients WithGrowth Hormone Deficiency (GHD)
Phase 3 Study Evaluating Once Weekly Somatrogon Compared to Daily Genotropin in Japanese Patients With Pediatric Growth Hormone Deficiency(pGHD)